Targeting the FcRn is a novel and promising approach for the treatment of a number of Ab-mediated neurological diseases due to selective IgG depletion and can additionally be used to extend the half-life and efficacy of therapeutic mAbs. Here, FCGRT is linked to nervous system disorder.